At Lipa Meir & Co ‘the life sciences team is practical, skilled, business savvy and learned’. The firm handles everything, from big data and cybersecurity issues to litigation, judicial reviews and regulatory matters, and it is increasingly involved in significant corporate transactions in the life sciences sector. A recent example is its work for a NASDAQ-listed pharmaceutical company on its $58m merger with an Israeli company that develops treatments for Parkinson’s disease. ’His human and professional qualities shine and guide clients in complex legal and business issues’, say clients of practice head Gary Copelovitz, who handled that transaction. Isaac Anidjer, who focuses on litigation, and commercial partner Meir Elbaum, also play pivotal roles in the practice.
Legal 500 Editorial commentary
- Profile
Testimonials
Collated independently by Legal 500 research team.
‘The life sciences team is practical, skilled, business savvy and learned.’
‘Gary Copelovitz's human and professional qualities shine and guide clients in complex legal and business issues. His experience over the years has only strengthened his passion for the law and the healthcare sector. It is a true pleasure to follow Gary's lead.’
'Very capable in coordinating cross border transactions; strong knowledge of market practices in Israel and in the US. Effective and efficient communicators. Deal-oriented.'
'Gary Copelovitz is a fantastic lawyer. He has a keen understanding of legal issues and is able to distill complex topics into digestible bites for clients to consider.'
Key clients
- Hepion Pharmaceuticals, Inc.
- Menorah Mivtachim Insurance Company Ltd.
- Al-Rad Medical Ltd.
- OPTM.RX Ltd.
- Exosomm Ltd.
- BlinkAid Ltd.
- Regenesis Ltd.
- AP Partners Fund LP
- Galil Okek Incubator
- Biopharma Credit PLC
Work highlights
Advising Galil Ofek, an Israeli Innovation Authority incubator that supports healthcare and life sciences start-ups in Northern Israel, on a range of corporate and commercial guidance, including establishing corporate entities and investments, fostering regional innovation and social change, with notable transactions involving companies like Regenesis Ltd., Sonosphere Ltd., BlinkAid Ltd., Droxy AI Ltd., Exosomm Ltd., BioArmix Ltd., and OPTM.RX Ltd., as well as strategic partnerships and fundraising.
Advised NASDAQ-listed Hepion Pharmaceuticals on its successful $58m merger with Israel-based Pharma Two B, a strategic union that strengthens their position in the global pharmaceutical market by combining Hepion's chronic liver disease treatments with Pharma Two B's innovative Parkinson's disease therapies, with plans for Pharma Two B to list on NASDAQ and advance its FDA licensing application following the merger's expected completion in late 2024.
Representing Biopharma Credit PLC in amending and restating its loan agreement with Urogen Pharma, having also advised on the 2022 issuance of a $100m senior secured loan.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Gary Copelovitz
Other key lawyers
Meir Elbaum; Isaac Anidjer